OBJECTIVE:Oxidized LDL (oxLDL) and oxLDL antibodies form immune complexes (IC) that reflect essential components in the development of atherosclerosis: dyslipidemia, oxidative stress and induction of a pro-inflammatory humoral immune response. We measured oxLDL in IC (oxLDL-IC) isolated from patients with type 1 diabetes to assess the relationship between oxLDL-IC and coronary artery calcification (CAC). METHODS:OxLDL was measured in IC isolated from baseline samples from a subgroup of 476 patients of the Diabetes Control and Complications Trial (DCCT). CAC was determined by computed tomography (CT) 11-20 years later. Multivariable log-binomial regression models were used to estimate the risk ratios associated with having a high CAC score with an increase of 1 standard deviation (SD) of the natural logarithm of oxLDL-IC. RESULTS: Multivariable regression models indicate that a 1 SD increase in the levels of oxLDL-IC was associated with a 37% increase in the risk of having high CAC score (RR=1.36; 95% CI: 1.12-1.67) at follow-up after adjustment for DCCT treatment group, retinopathy/AER groups, gender and CT scanning site as well as baseline age, diabetes duration and HbA1C %. Further adjustment for smoking status, blood pressure and LDL resulted in a risk ratio of 1.23 (95% CI: 1.01-1.50) which remained statistically significant indicating that baseline oxLDL-IC is independently associated with the development of CAC. DISCUSSION: Increased levels of oxLDL-IC are associated with the development of coronary calcification. This observation reinforces previously published clinical and experimental data demonstrating that oxLD-IC has pro-inflammatory and proatherogenic properties. Published by Elsevier Ireland Ltd.
RCT Entities:
OBJECTIVE: Oxidized LDL (oxLDL) and oxLDL antibodies form immune complexes (IC) that reflect essential components in the development of atherosclerosis: dyslipidemia, oxidative stress and induction of a pro-inflammatory humoral immune response. We measured oxLDL in IC (oxLDL-IC) isolated from patients with type 1 diabetes to assess the relationship between oxLDL-IC and coronary artery calcification (CAC). METHODS: OxLDL was measured in IC isolated from baseline samples from a subgroup of 476 patients of the Diabetes Control and Complications Trial (DCCT). CAC was determined by computed tomography (CT) 11-20 years later. Multivariable log-binomial regression models were used to estimate the risk ratios associated with having a high CAC score with an increase of 1 standard deviation (SD) of the natural logarithm of oxLDL-IC. RESULTS: Multivariable regression models indicate that a 1 SD increase in the levels of oxLDL-IC was associated with a 37% increase in the risk of having high CAC score (RR=1.36; 95% CI: 1.12-1.67) at follow-up after adjustment for DCCT treatment group, retinopathy/AER groups, gender and CT scanning site as well as baseline age, diabetes duration and HbA1C %. Further adjustment for smoking status, blood pressure and LDL resulted in a risk ratio of 1.23 (95% CI: 1.01-1.50) which remained statistically significant indicating that baseline oxLDL-IC is independently associated with the development of CAC. DISCUSSION: Increased levels of oxLDL-IC are associated with the development of coronary calcification. This observation reinforces previously published clinical and experimental data demonstrating that oxLD-IC has pro-inflammatory and proatherogenic properties. Published by Elsevier Ireland Ltd.
Authors: Aklilu A Yishak; Tina Costacou; Gabriel Virella; Janice Zgibor; Linda Fried; Michael Walsh; Rhobert W Evans; Maria Lopes-Virella; Valerian E Kagan; James Otvos; Trevor J Orchard Journal: Nephrol Dial Transplant Date: 2005-09-06 Impact factor: 5.992
Authors: Antonio F Saad; Gabriel Virella; Charlyne Chassereau; Robert J Boackle; Maria F Lopes-Virella Journal: J Lipid Res Date: 2006-06-27 Impact factor: 5.922
Authors: M F Lopes-Virella; G Virella; T J Orchard; S Koskinen; R W Evans; D J Becker; K Y Forrest Journal: Clin Immunol Date: 1999-02 Impact factor: 3.969
Authors: Gabriel Virella; M Brooks Derrick; Virginia Pate; Charlyne Chassereau; Suzanne R Thorpe; Maria F Lopes-Virella Journal: Clin Diagn Lab Immunol Date: 2005-01
Authors: Arpita Basu; Ionut Bebu; Alicia J Jenkins; Julie A Stoner; Ying Zhang; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Matthew J Budoff; Petar Alaupovic; Timothy J Lyons Journal: J Lipid Res Date: 2019-06-15 Impact factor: 5.922
Authors: Elke R Fährmann; Laura Adkins; Cameron J Loader; Hyoil Han; Kevin M Rice; James Denvir; Henry K Driscoll Journal: Diabetes Res Clin Pract Date: 2014-10-23 Impact factor: 5.602
Authors: Maria F Lopes-Virella; Ionut Bebu; Kelly J Hunt; Gabriel Virella; Nathaniel L Baker; Barbara Braffett; Xiaoyu Gao; John M Lachin Journal: Diabetes Date: 2019-06-19 Impact factor: 9.461
Authors: Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; Gabriel Virella; Thomas Moritz Journal: Atherosclerosis Date: 2012-08-21 Impact factor: 5.162
Authors: Kelly J Hunt; Nathaniel L Baker; Patricia A Cleary; Richard Klein; Gabriel Virella; Maria F Lopes-Virella Journal: Diabetes Care Date: 2015-04-07 Impact factor: 19.112